Acadian Asset Management
CRSP icon

Acadian Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Acadian Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-633
Closed -$53K – 2222
2020
Q3 		$53K Sell
633
-8,541
-93% -$758K ﹤0.01% 1841
2020
Q2 		$674K Sell
9,174
-137,092
-94% -$8.02M ﹤0.01% 1091
2020
Q1 		$6.2M Buy
+146,266
New +$7.55M 0.04% 353
2018
Q2 		– Sell
-111
Closed -$5K – 1731
2018
Q1 		$5K Buy
+111
New +$4.58K ﹤0.01% 1616

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Acadian Asset Management's CRSP Position: Q4 2020 in Review

Acadian Asset Management sold out of CRISPR Therapeutics (CRSP) in Q4 2020, closing a stake of 633 shares — an estimated $53K sold.

Acadian Asset Management first reported a position in CRSP in Q1 2018 and held it in 4 quarters. The position peaked at $6.2M in Q1 2020. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

  • Acadian Asset Management reported no remaining CRISPR Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Acadian Asset Management sold 633 CRISPR Therapeutics shares in Q4 2020, an estimated $53K.
  • Acadian Asset Management first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 4 quarters.
  • Acadian Asset Management's CRISPR Therapeutics position peaked at $6.2M in Q1 2020.
  • 412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Acadian Asset Management's 13F filing for Q4 2020, filed 11 Feb 2021.